



Berger-Schaffitzel, C. H., & et al. (2021). Structural biology in the fight against COVID-19. *Nature Structural and Molecular Biology*, 28(1), 2–7. <https://doi.org/10.1038/s41594-020-00544-8>

Peer reviewed version

Link to published version (if available):
[10.1038/s41594-020-00544-8](https://doi.org/10.1038/s41594-020-00544-8)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Nature Research at <https://doi.org/10.1038/s41594-020-00544-8> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

FEATURE – SARS-CoV-2

Author name(s): Christiane Schaffitzel

Affiliation:

¹ School of Biochemistry, University of Bristol, 1 Tankard's Close, Bristol BS8 1TD, UK.

² Bristol Synthetic Biology Centre BrisSynBio, 24 Tyndall Ave, Bristol BS8 1TQ, UK.

Correspondence:

e-mail: cb14941@bristol.ac.uk

TEXT:

Structural and computational biology play key roles in elucidating molecular mechanisms of disease phenotypes and in driving drug discovery. This is exemplified by the current fast-paced efforts to respond to the COVID-19 pandemic. To aid these endeavors, the University of Bristol set up a COVID Emergency group (UNCOVER), coordinated by Bristol clinician Adam Finn, that initiated multi-disciplinary collaborations among virologists, chemists, physicians, pharmacologists and others to accelerate our understanding of COVID-19 and to design tailored treatments urgently needed to overcome the crisis. In our contribution, we discovered a druggable pocket in the SARS-CoV-2 spike (S) glycoprotein, the viral component that mediates interaction with the cellular ACE2 receptor and that is essential for infection [1]. In our cryo-EM structure of S, this pocket was occupied by linoleic acid (LA), an essential poly-unsaturated free fatty acid (FFA). LA stabilized S in a locked conformation that is incompatible with ACE2 binding and is thus considered 'non-infective'. Intriguingly, LA synergizes with remdesivir, the first drug approved for COVID-19 treatment, to block viral replication in cells [1]. Our discovery has actionable implications: the data suggest that LA could act as a prophylactic antiviral. Intriguingly, sera of COVID-19 patients have decreased levels of FFAs, including LA [2]; therefore LA

supplementation may be beneficial. Small molecules binding the FFA-binding pocket (LA mimics) have potential as future antivirals as they might lock S in a non-infective conformation. Finally, The body metabolizes LA to eicosanoids, including prostaglandin, key molecules in immune modulation. In addition, LA-based phospholipids maintain fluidity of cell membranes and surface tension in the lung. While more research is required to decipher the interplay of FFAs, SARS-CoV-2 and COVID-19 pathology. Thus, targeting the LA metabolic axis could help prevent rampant inflammatory responses in severe cases of COVID-19 and reduce respiratory distress and the risk of pneumonia in patients. Finally, LA mimics have potential as future small molecule antivirals as they might lock S in a non-infective conformation. While more research is required to decipher the interplay of FFA, SARS-CoV-2 and COVID-19 pathology, our research provides avenues to explore in the fight of COVID-19.

Commented [AS1]: Moved up, because I think the transition to LA supplementation works very well, while the pocket-binding drugs cover another aspect of the work.

Commented [CB2R1]: I agree, it works well this way.

References:

1. Toelzer, C. *et al.* Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. *Science*, DOI: [10.1126/science.abd3255](https://doi.org/10.1126/science.abd3255) (2020).
2. B. Shen *et al.*, Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. *Cell* **182**, 59-72 (2020).

Forms:

Competing interests? No

<https://www.nature.com/documents/nr-competing-interests.pdf>

Copyright assignment form

<http://www.nature.com/documents/sna-copyright-assignment.docx>

Photograph

License required? No

Credit to: University of Bristol